Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : C3 ( CTHR ) Diamond in the rough? -- Ignore unavailable to you. Want to Upgrade?

To: Ron who wrote (140)	7/29/1998 2:31:00 PM
From: John M. Butler	Read Replies (1) \| Respond to of 226

Given the fact that C3 has almost $6 per share in current assets (from the IPO), it seems that there is very little downside risk in this stock at these levels. Even if sales don't skyrocket, the continued sale of the test instruments coupled with the sale of product over the next quarter will give us a pretty good shot at break even earnings before the end of the year. I think we have a sleeper here ! BTW, does anybody know what percentage of R&D expenses were offset by the sale of stones this past quarter? I haven't seen the full quarterly report, so I'm not sure how that was reported. Thanks. JB